Jeremy Treger
Cardiovascular Disease · Chicago, ILNPI 1730672965
Payments from drug & device makers
Across 235 payments — averaging $163.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$14K
- Medtronic$12K
- Boston Scientific$10K
- Biosense Webster, Inc.$769
- Biotronik Inc.$473
- AstraZeneca$226
- plus $844 from 14 others
What the payments were for
- Grants$28,97076%
- Travel & lodging$1,6454%
- Food & beverage$6,94718%
- Education$7592%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 53 | $13,821 |
| Medtronic | 66 | $12,015 |
| Boston Scientific | 6 | $10,173 |
| Biosense Webster, Inc. | 40 | $769 |
| Biotronik Inc. | 8 | $473 |
| AstraZeneca | 15 | $226 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $140 |
| Pfizer | 9 | $130 |
| Amgen | 7 | $109 |
| Johnson & Johnson | 7 | $104 |
| Lantheus Medical Imaging, Inc. | 5 | $89 |
| Novartis | 3 | $76 |
| Philips North America LLC | 2 | $53 |
| Merck | 2 | $28 |
| Cardiva Medical, Inc. | 1 | $23 |
| Edwards Lifesciences | 1 | $23 |
| Cordis US CORP. | 1 | $19 |
| Heartflow, Inc. | 1 | $17 |
| Vektor Medical Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL BRADY$5,000
- Micra$785
- ENSITE$389
- SelectSecure$274
- ENSITE PRECISION$211
- COBALT DR MRI SURESCAN$183
- AVEIR$123
- Solia$123
- Edora$123
- BioMonitor$123
- Rivacor$123
- Acticor$123
- AZURE XT DR MRI SURESCAN$116
How this compares
$38,321 in reported general payments places this provider in the 85th percentile of 932 cardiovascular disease providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $18,551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $130 | $18,55111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Chicago
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Nitasha SarswatChicago$2M
- Sanjiv ShahChicago$1.2M
- Sandeep NathanChicago$1.1M
- Boaz AvitallChicago$663K
- Ravi PatelChicago$488K
- Lubna ChoudhuryChicago$476K
- Akhil NarangChicago$427K
- Amit AminChicago$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.